Discussant: CETP inhibition-is it time for a revival? AHA Conference Repository

American Heart Association

114

Final ID:

Discussant: CETP inhibition-is it time for a revival?

Watson, Karol ( UCLA , Redondo Beach , California , United States )

Author Disclosures:

KAROL WATSON:

DO have relevant financial relationships

Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Nicholls Stephen, Brunham Liam, Wuerdeman Erin, Neild Annie, Kling Douglas, Hsieh Andrew, Ference Brian, Laufs Ulrich, Banach Maciej, Mehran Roxana, Catapano Alberico, Nelson Adam, Davidson Michael, Ditmarsch Marc, Kastelein John, Ballantyne Christie, Ray Kausik, Navar Ann Marie, Nissen Steven, Goldberg Anne

More abstracts from these authors:

Don't Let Up: An Ounce of Prevention is Worth a Pound in Cardio-Oncology

Watson Karol, Lloyd-jones Donald

2025 AHA/ACC BP Guideline: The 12 Key Takeaways You Can't Miss

Watson Karol